KK3A.F Cytokinetics Incorporated

Healthcare Biotechnology Frankfurt Exchange
50.00 EUR
Close of Nov 13, 2026
47.99 75.62
Market cap
EUR 6.97B
P/E
-
P/B
60.23x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KK3A.F undervalued?

Graham number

The Graham number of Cytokinetics Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cytokinetics Incorporated fundamental analysis

No fundamental analysis for Cytokinetics Incorporated yet.

Cytokinetics Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cytokinetics Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omec…

Full company profile